Browse by Series:

OncLive News Network On Location: ASH 2019 Day 2

Gina Columbus
Published: Monday, Dec 09, 2019



Today-

We are on site at the Orange County Convention Center in Orlando, Florida, at the 2019 ASH Annual Meeting!

We’ll be recapping some of the top news presented each day during the meeting, and soon we’ll speak with Dr Matthew Davids on some of the biggest chronic lymphocytic leukemia studies, and Dr Bijal Shah on some pivotal abstracts in mantle cell lymphoma and CAR T-cell therapy.

Welcome to OncLive News Network! I'm Gina Columbus.

In a subgroup analysis of the AUGMENT trial, the combination of lenalidomide and rituximab, known as R-squared, was found to be superior to single-agent rituximab in terms of progression-free survival, overall response rate, and complete response, in patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma, irrespective of age.

The results seen in patients at least 70 years old were similar to those reported in the overall study population, demonstrating that R-squared maintains efficacy in patients despite higher unfit status and lower overall lenalidomide treatment or exposure.

Phase I/II findings showed that lenalidomide plus obinutuzumab is safe and effective in patients with relapsed indolent lymphoma. Several patients achieved prolonged remission, including those who relapsed after 2 or more prior lines of therapy. Additionally, adverse events were similar to what has been seen with the combination of lenalidomide and rituximab.

Preliminary results of a phase I/II study showed that the triplet of umbralisib, ublituximab, and venetoclax can provide undetectable minimal residual disease after 12 cycles and has a good tolerability profile, suggesting that it is an effective treatment plan for this population. Ongoing enrollment is focusing on patients who have relapsed on BTK inhibitors, and a multicenter trial is planned to further develop the triplet regimen.

The next-generation BTK inhibitor zanubrutinib demonstrated efficacy in patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma who harbored 17p deletions, according to an arm of the international Sequoia trial. The preliminary results also showed that the agent was well tolerated.

The next-generation, highy selective, non-covalent BTK inhibitor LOXO-305 demonstrated proof-of-concept evidence of efficacy and a favorable safety profile in patients with heavily pretreated chronic lymphocytic leukemia and mantle cell lymphoma. The benefit was also observed in patients with acquired resistance to available BTK inhibitors and venetoclax.

Also, in chronic lymphocytic leukemia, the investigational CAR T-cell therapy lisocabtagene maraleucel rapidly achieved complete responses and undetectable minimal residual disease in heavily pretreated patients with relapsed/refractory CLL or small lymphocytic lymphoma, according to findings of the phase I/II Transcend CLL 004 trial. Moreover, the durable responses lasted longer than 6 months.

That’s all for today. Stay tuned for tomorrow’s OncLive News Network: On Location, where we will sit down with Dr John Mascarenhas on the latest in myeloproliferative neoplasms, and Dr Stephen Ansell on some practice-changing non-Hodgkin lymphoma studies.

Thank you for watching OncLive News Network! I'm Gina Columbus.
SELECTED
LANGUAGE
Slider Left
Slider Right


Today-

We are on site at the Orange County Convention Center in Orlando, Florida, at the 2019 ASH Annual Meeting!

We’ll be recapping some of the top news presented each day during the meeting, and soon we’ll speak with Dr Matthew Davids on some of the biggest chronic lymphocytic leukemia studies, and Dr Bijal Shah on some pivotal abstracts in mantle cell lymphoma and CAR T-cell therapy.

Welcome to OncLive News Network! I'm Gina Columbus.

In a subgroup analysis of the AUGMENT trial, the combination of lenalidomide and rituximab, known as R-squared, was found to be superior to single-agent rituximab in terms of progression-free survival, overall response rate, and complete response, in patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma, irrespective of age.

The results seen in patients at least 70 years old were similar to those reported in the overall study population, demonstrating that R-squared maintains efficacy in patients despite higher unfit status and lower overall lenalidomide treatment or exposure.

Phase I/II findings showed that lenalidomide plus obinutuzumab is safe and effective in patients with relapsed indolent lymphoma. Several patients achieved prolonged remission, including those who relapsed after 2 or more prior lines of therapy. Additionally, adverse events were similar to what has been seen with the combination of lenalidomide and rituximab.

Preliminary results of a phase I/II study showed that the triplet of umbralisib, ublituximab, and venetoclax can provide undetectable minimal residual disease after 12 cycles and has a good tolerability profile, suggesting that it is an effective treatment plan for this population. Ongoing enrollment is focusing on patients who have relapsed on BTK inhibitors, and a multicenter trial is planned to further develop the triplet regimen.

The next-generation BTK inhibitor zanubrutinib demonstrated efficacy in patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma who harbored 17p deletions, according to an arm of the international Sequoia trial. The preliminary results also showed that the agent was well tolerated.

The next-generation, highy selective, non-covalent BTK inhibitor LOXO-305 demonstrated proof-of-concept evidence of efficacy and a favorable safety profile in patients with heavily pretreated chronic lymphocytic leukemia and mantle cell lymphoma. The benefit was also observed in patients with acquired resistance to available BTK inhibitors and venetoclax.

Also, in chronic lymphocytic leukemia, the investigational CAR T-cell therapy lisocabtagene maraleucel rapidly achieved complete responses and undetectable minimal residual disease in heavily pretreated patients with relapsed/refractory CLL or small lymphocytic lymphoma, according to findings of the phase I/II Transcend CLL 004 trial. Moreover, the durable responses lasted longer than 6 months.

That’s all for today. Stay tuned for tomorrow’s OncLive News Network: On Location, where we will sit down with Dr John Mascarenhas on the latest in myeloproliferative neoplasms, and Dr Stephen Ansell on some practice-changing non-Hodgkin lymphoma studies.

Thank you for watching OncLive News Network! I'm Gina Columbus.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x